And then what’s crucial is what in technical terms is called the variable allele frequency. That means if we know, because we sequenced the tumor, let’s say 100 times deep, so every site in the genome was sequenced 100 times. So we know rather precisely whether the tumor sample that the surgeon or the biopsy person has given us is 25% tumor material or 30% or 40%. So we know precisely whether a certain rearrangement is present at all the tumor cells or only in a subset of them. And we basically base everything on the ones that are clonal in the sample so that as far as we can know from that sample are present in all of the tumor material. Does that answer your question?
Operator: Our next question comes from Roy Buchanan with JMP Securities. Please proceed.
Roy Buchanan: Hi. Great. Thanks for taking the questions. I guess the first one is financial. How should we think about the expense trajectory for 2023? How much are you planning to spend on implementing The RNA Printer in the clinic? Can you remind us where the GMP 4 site is in development and how much is funded by the German government? And then finally on the printer, have you had any engagement with the FDA or plans to engage ahead of potentially using it in a trial? Thanks.
Pierre Kemula: Hi, Roy. How are you? It’s Pierre. I’ll take a couple of questions. I’ll probably pass on the FDA discussion. We don’t break down the allocation of our cash per item, like the printer or GMP 4. But when we look at the year to come, we are closing our budget process now. So it’s still subject to some changes, but the idea is that with the cash position we have, we should be able to sell through the whole of next year and a bit of the following year, right. And at the same time, make sure that we continue to fuel the strengthening of the platform, and I think we went through long strides in the presentation to try and give you a sense of what we’re doing. And on GMP 4, so the way it works, you’re right, we have this pandemic preparedness, contract with the German government.
The idea here is that we basically pay upfront and then we get yearly fee from the German government, right? So we would have to make sure that the client is ready to go and fully, I would say, resourced, but then all that is more than paid for by the German government.
Franz-Werner Haas: Yes, so there was a question on do we discuss with the FDA on the printer, and this is — maybe, Ulrike, you can take that one.
Ulrike Gnad-Vogt: Yes. So we plan several health authority interactions during the course of ’23, including interactions with FDA, and this will also address questions related to the printer.
Roy Buchanan: Okay, great. And then maybe a follow up. The two cancer Phase 1s that you’re talking about, where are they going to be conducted and what’s the delivery? Is it IM, IV? Are you using LNP? It sounds like you’re using LNP. Thanks.
Ulrike Gnad-Vogt: Yes, actually the countries and locations will be communicated in due time. The second part of your question was about the LNP, and there we will use the same LNP formulation we are using for our current prophylactic vaccine candidates. And that will be injected intramuscularly.
Roy Buchanan: Great. Thank you.
Operator: Our next question comes from Zhiqiang Shu with Berenberg. Please proceed.
Zhiqiang Shu: Thank you very much. I have two questions. First on the cancer vaccine pipeline online today, I wonder for the two proof of principle studies you’re going to do the first on glioblastoma, I guess can you provide additional rationale on why you’re going to first use glioblastoma as a proof of concept. And we all know it is a tough cancer to crack. Any color there would be great?
